SIONNA THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
SIONNA THERAPEUTICS, INC. (SION) reported Increase (Decrease) in Accrued Liabilities of -$759.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $2.70M, a 27.61% increase year-over-year.
- SIONNA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$3.46M.
- SIONNA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.49M, a 21.49% decline year-over-year.
- SIONNA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $1.68M, a 20.80% increase year-over-year.
- SIONNA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $1.98M, a 82.87% increase from fiscal 2024.
- SIONNA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $1.08M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$759.00K 10-Q · filed 2026-08-06 | $1.73M derived: sum of 3 quarters · filed 2026-08-06 | $3.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.46M 10-Q · filed 2026-05-12 | -$971.00K derived: sum of 2 quarters · filed 2026-05-12 | $713.00K derived: sum of 3 quarters · filed 2026-05-12 | $2.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.18M derived: sum of 2 quarters · filed 2026-03-02 | $6.29M derived: sum of 3 quarters · filed 2026-08-06 | $1.98M 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.80M derived: sum of 2 quarters · filed 2026-08-06 | -$517.00K 10-Q · filed 2025-11-05 | $2.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.20M 10-Q · filed 2026-08-06 | $973.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$4.32M 10-Q · filed 2026-05-12 | -$1.15M derived: sum of 2 quarters · filed 2026-05-12 | $248.00K derived: sum of 3 quarters · filed 2026-05-12 | -$618.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.57M derived: sum of 2 quarters · filed 2026-03-02 | $3.70M derived: sum of 3 quarters · filed 2026-03-02 | $1.08M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $528.00K derived: sum of 2 quarters · filed 2025-11-05 | -$2.09M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$866.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$3.49M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$2.62M 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |